Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
EHDN2018 DISEASE NETWORK PROJECTS LOGIN
 
 
  
EHDN2012 - Documents - Presentations -
--->Новости
[-]Проект
--->Спонсор
--->[-]Исполнительный комитет
--->Arnesen
--->Blumenstein
--->Humbert
--->Jones
--->Kulisevsky
--->Mariotti
--->Muehlbaeck
--->Reilmann
--->Roos
--->Rosser
--->Weydt
--->Capper-Loup
--->Feihle
--->Levey
--->McLean
--->Документы
--->[+]Writing Committee Strategic ...
--->[+]Комитет по Науке и Биоэтик...
--->Центральное координирован...
--->Языковое координирование
--->Fellowship Programme
--->[+]Конституция
--->[+]Bыборы/Выдвижение кандида...
--->[-]Члены ЕHDN
--->Запрос
[-]Подразделения
--->[+]Austria
--->[-]Belgium
--->Coordination
--->HD Associations
--->Antwerpen
--->[-]Bierbeek
--->Contacts
--->[-]Documents
--->Informed Consent
--->ERB Templates
--->ERB
--->Brussel - VUB
--->Bruxelles - Saint-Luc
--->Bruxelles - Erasme (UCL)
--->Charleroi
--->Leuven
--->Liège (Luik)
--->[+]Czech Republic
--->[+]Denmark
--->[+]Finland
--->[+]France
--->[-]Germany
--->Coordination
--->HD Associations
--->Standard of Care
--->Aachen
--->Berlin
--->Bochum
--->Bonn
--->Dresden
--->Dinslaken
--->Düsseldorf
--->Erlangen
--->Freiburg
--->Hamburg
--->Hannover
--->HH-Heiligenhafen
--->Itzehoe
--->Marburg-Uni
--->[+]Lübeck
--->Marburg-KPP
--->Mainz
--->Munich
--->München-LMU
--->Münster
--->Rostock
--->Taufkirchen
--->Ulm
--->[+]Würzburg
--->[+]Ireland
--->[+]Italy
--->[-]Netherlands
--->Coordination
--->HD Associations
--->Enschede
--->Groningen
--->Leiden
--->[+]Maastricht
--->Nijmegen
--->[+]Norway
--->[-]Poland
--->Coordination
--->[+]HD Association
--->Gdansk
--->Katowice
--->[+]Krakow
--->Poznan
--->Warsaw - MU
--->Warsaw - IPiN
--->[-]Portugal
--->Coordination
--->Coimbra
--->Lisbon - Central
--->Lisbon - Fernando-Fonseca...
--->Lisbon - Santa Maria
--->Porto - São João
--->Vila Real
--->[-]Russia
--->[+]Coordination
--->[+]HD Associations
--->[-]Kazan
--->Dates
--->[+]Moscow
--->[+]Nizhny Novgorod
--->[+]Ufa
--->[+]Voronezh
--->[-]Spain
--->Coordination
--->HD Associations
--->Alicante
--->Badajoz
--->Barcelona - Bellvitge
--->Barcelona - Clinic i Provincia...
--->Barcelona - Mutua de Terra...
--->Barcelona - Santa Creu i Sa...
--->Barcelona - Merced
--->Bilbao
--->Burgos
--->Canaries
--->Granada
--->Fuenlabrada
--->[+]Madrid-BTCIEN
--->Madrid - Clínico
--->Madrid - FJD
--->Madrid - RyC
--->Murcia
--->Oviedo
--->Palma de Mallorca
--->Pamplona
--->Santiago
--->Sevilla
--->Sevilla-HUVRocio
--->Sevilla-St-Ana
--->Valencia
--->Zaragoza
--->[+]Sweden
--->[+]Switzerland
--->[+]U.K.
--->[+]Outside Europe
[-]Рабочие группы
--->[+]Advanced HD
--->[+]Behavioural Phenotype
--->[+]Biological Modifiers
--->[+]Biomarkers
--->[+]Brain and Tissue Banking
--->[+]Cognitive Phenotype
--->[+]Environmental Modifiers
--->[+]Functional Ability
--->[+]Genetic Testing
--->[+]Genetic Modifiers
--->[+]Health Economics
--->[+]Heated TF
--->[+]Imaging
--->[+]Juvenile HD
--->[+]Motor Phenotype
--->[+]Neuroprotective Therapy
--->[+]Physiotherapy
--->[-]Quality of Life
--->[-]Dates
--->[+]Meetings
--->[+]Standard of Care
--->[+]Surgical Approaches
--->[+]Symptomatic Research
--->[+]Young Adults
[-]События
--->[+]EHDN 2018
--->[-]EHDN 2016
--->Announcement
--->Introduction
--->Registration
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Floor plan
--->[+]Overduin Registration
--->CME points
--->Sponsoring
--->Travel Information
--->Hotel booking
--->Social activities
--->Reimbursement
--->[+]Abstract Submission
--->Contacts
--->Documents
--->Feedback
--->EHDN 2014
--->[-]EHDN 2012
--->Introduction
--->Announcement
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Important Dates
--->Registration
--->[+]Travel & Accommodation
--->[+]EHA Registration
--->EHA Programme
--->Reception Dinner
--->About Stockholm
--->[+]Abstract Submission
--->Reimbursement
--->[-]Documents
--->Handouts
--->Presentations
--->[+]Posters
--->Contacts
--->Feedback & Evaluation
--->[-]EHDN 2010
--->Introduction
--->Programme I
--->Programme II
--->Additional Meetings
--->Registration
--->EHA Programme
--->[+]EHA Registration
--->Plenary Dinner
--->Social Programme
--->Important Dates
--->[-]Abstract Submission
--->Reimbursement
--->Hotel Booking
--->[+]Travel and Location
--->[+]About Prague
--->Documents
--->Committees
--->Contact
--->Feedback & Evaluation
--->[-]EHDN 2008
--->Programme
--->Additional Meetings
--->EHA Programme
--->Social Programme
--->Kids Programme
--->Important Dates
--->Voting
--->Reimbursement
--->[+]Registration
--->[+]Abstract Submission
--->Evaluation & Feedback
--->[+]Travel and Location
--->[+]About Lisbon
--->[+]Documents
--->Committees
--->Contact
--->[+]EHDN 2007
--->[+]EHDN 2006
--->[-]EHDN 2005
--->Final Programme
--->Plenary Dinner
--->Registration
--->Working Groups
--->Meeting Venue
--->Manchester
--->Evaluation & Feedback
--->[+]EHDN 2004
[-]Контакты
--->Contact Form
--->Chat Rooms
--->Mailinglists - public
--->Newsletter
--->Работа в ЕHDN
датаописаниеразмеравтор документ 
11.04.13Plenary Session I: ‘A look ahead’33blankintext/x-cms-notePlenary-Session-I 
11.04.13Frequency of Huntington Disease - Greater than you think9 kBblankinapplication/pdfehdn-2012-hayden-empty-file 
11.04.13What are we really looking for in an HD drug?9 kBblankinapplication/pdfehdn-2012-sampaio-empty-file 
11.04.13Care, coping and research in HD – the earlier the better!9 kBblankinapplication/pdfehdn-2012-duerr-empty-file 
11.04.13Plenary Session II: ‘Frontiers in biology and their relevance to Huntington’s disease’ 33blankintext/x-cms-notePlenary-Session-II 
11.04.13Longevity pathways and their relevance to human disease9 kBblankinapplication/pdfehdn-2012--aguilaniu-empty-file 
11.04.13RNA toxicity in poly-Q disorders3.3 MBblankinapplication/pdfehdn-2012-krzyzosiak 
11.04.13Post-translational modifications and proteolysis of huntingtin9 kBblankinapplication/pdfehdn-2012-truant-empty-file 
11.04.13Plenary Session III: ‘Science practice at EHDN’ 33blankintext/x-cms-notePlenary-Session-III 
11.04.13Scientific strategy of EHDN126 kBblankinapplication/pdfehdn-2012-bronzova 
11.04.13Juvenile HD Working Group441 kBblankinapplication/pdfehdn-2012-quarrell 
11.04.13Advanced HD Working Group9 kBblankinapplication/pdfehdn-2012-youssov-empty-file 
11.04.13Animal studies on the effects of physiotherapy9 kBblankinapplication/pdfehdn-2012-brooks-empty-file 
11.04.13Human physiotherapy studies9 kBblankinapplication/pdfehdn-2012-busse-empty-file 
11.04.13Short Communications I: 'Scientific Presentations: 10’ and 5’ questions – selected from submissions' 33blankintext/x-cms-noteShort-Communications-I 
11.04.13Default-mode network changes in preclinical Huntington´s disease9 kBblankinapplication/pdfehdn-2012-orth-empty-file 
11.04.13Longitudinal functional and connectivity changes during working memory performance in HD9 kBblankinapplication/pdfehdn-2012-georgiou-karistianis-empty-f... 
11.04.13Better global and cognitive functioning for choreatic compared to hypokinetic- rigid HD9 kBblankinapplication/pdfehdn-2012-t-hart-empty-file 
11.04.13Critical consideration of the criteria for the motor diagnosis of HD9 kBblankinapplication/pdfehdn-2012-paulsen-empty-file 
11.04.13Plenary Session IV: Keynote presentations33blankintext/x-cms-notePlenary-Session-IV 
11.04.13Update on stem cell research: clinical potentials9 kBblankinapplication/pdfehdn-2012-brundin-empty-file 
11.04.13Cognitive alterations in HD9 kBblankinapplication/pdfehdn-2012-stout-empty-file 
11.04.13Roundup I33blankintext/x-cms-noteRoundup-I 
11.04.13Lessons of the day9 kBblankinapplication/pdfehdn-2012-wild-empty-file 
11.04.13Breakfast teaching courses Sat33blankintext/x-cms-noteBreakfast-teaching-courses-sat 
11.04.13Clinical management of Huntington’s disease9 kBblankinapplication/pdfehdn-2012-nance-empty-file 
11.04.13Differential diagnosis of chorea9 kBblankinapplication/pdfehdn-2012-walker-empty-file 
11.04.13Behavioral assessment and management of behavioral issues9 kBblankinapplication/pdfehdn-2012-anderson-empty-file 
11.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-craufurd-empty-file 
11.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-reilmann-empty-file 
11.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-j-thompson-empty-file 
11.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-quarrell-empty-file 
11.04.13Plenary Session V: ‘Understanding and manipulating the pathogenic process in Huntington’s disease’ 33blankintext/x-cms-notePlenary-Session-V 
11.04.13Huntingtin7.9 MBblankinapplication/pdfehdn-2012-cattaneo 
11.04.13Post-translational modifications of huntingtin9 kBblankinapplication/pdfehdn-2012-saudou-empty-file 
11.04.13Stem cells for basic research on HD1.8 MBblankinapplication/pdfehdn-2012-ellerby 
11.04.13Stem cells for basic research on HD9 kBblankinapplication/pdfehdn-2012-l-thompson-empty-file 
11.04.13Plenary Session VI: Keynote presentations33blankintext/x-cms-notePlenary-Session-VI 
11.04.13Keynote presentations9 kBblankinapplication/pdfehdn-2012-aronin-empty-file 
11.04.13Updates on lowering huntingtin (htt) levels9 kBblankinapplication/pdfehdn-2012-davidson-empty-file 
11.04.13Short communications II: Scientific presentations33blankintext/x-cms-noteShort-communications-II 
11.04.13HDAC4 interacts with huntingtin and HDAC4 reduction decreases cytoplasmic aggregation and rescues synaptic dysfunction in HD mouse models9 kBblankinapplication/pdfehdn-2012-bates-empty-file 
11.04.13Aging pathway and poly-Q neurotoxicity656 kBblankinapplication/pdfehdn-2012-nollen 
11.04.13NeuroNet and its potential for the study of neurodegeneration9 kBblankinapplication/pdfehdn-2012-wanker-empty-file 
11.04.13Phenotyping neural networks in an ovine model of HD9 kBblankinapplication/pdfehdn-2012-perentos-empty-file 
11.04.13Plenary Session VII: ‘Therapeutic development programs in Huntington’s Disease’33blankintext/x-cms-notePlenary-Session-VII 
11.04.13Overview of CHDI drug development programs3.5 MBblankinapplication/pdfehdn-2012-pacifici 
11.04.13Htt lowering: Medtronic-Alnylam/Isis/CHDI9 kBblankinapplication/pdfehdn-2012-mcdonald-empty-file 
11.04.13Sirt1-inhibition: SienaBiotech9 kBblankinapplication/pdfehdn-2012-caricasole-empty-file 
11.04.13PDE-10-inhibition: Pfizer9 kBblankinapplication/pdfehdn-2012-schmidt-empty-file 
11.04.13PDE-4-inhibition: GSK9 kBblankinapplication/pdfehdn-2012-gray-empty-file 
11.04.13Bupropion: ACTION-HD9 kBblankinapplication/pdfehdn-2012-priller-empty-file 
11.04.13PREQUEL EHDN9 kBblankinapplication/pdfehdn-2012-ross-empty-file 
11.04.13Reach2HD PBT29 kBblankinapplication/pdfehdn-2012-stout-empty-file 
11.04.13Dopaminergic stabilization in HD: pridopidine9 kBblankinapplication/pdfehdn-2012-kieburtz-empty-file 
08.04.13Plenary Session VIII: EHDN Business Meeting33blankintext/x-cms-notePlenary-Session-VIII 
08.04.13EHDN Update - EC elections, SBAC elections, Structure of EHDN9 kBblankinapplication/pdfehdn-2012-landwehrmeyer-empty-file 
08.04.13Presentation of the HDYO website2.5 MBblankinapplication/pdfehdn-2012-ellison 
08.04.13Standards of Care9 kBblankinapplication/pdfehdn-2012-rea-empty-file 
08.04.13Roundup II33blankintext/x-cms-noteRoundup-II 
08.04.13Lessons of the day9 kBblankinapplication/pdfehdn-2012-wild-empty-file 
08.04.13Breakfast teaching courses Sun33blankintext/x-cms-noteBreakfast-teaching-courses-sun 
08.04.13Drug discovery and development process9 kBblankinapplication/pdfehdn-2012-kwak-empty-file 
08.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-craufurd-empty-file 
08.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-reilmann-empty-file 
08.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-thompson-empty-file 
08.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-quarrell-empty-file 
08.04.13HD for Basic Scientists9 kBblankinapplication/pdfehdn-2012-landwehrmeyer-empty-file 
08.04.13Common issues/problems/inconsistencies in HD assessments9 kBblankinapplication/pdfehdn-2012-ferreira-empty-file 
08.04.13Plenary Session IX: ‘Tools and outcome to monitor disease progression and response to therapy’33blankintext/x-cms-notePlenary-Session-IX 
08.04.13Brain imaging as a potential marker for HD (PET)9 kBblankinapplication/pdfehdn-2012-varrone-empty-file 
08.04.13MRI as a potential marker for HD971 kBblankinapplication/pdfehdn-2012-scahill 
08.04.13Defining predictors of disease1.9 MBblankinapplication/pdfehdn-2012-tabrizi 
08.04.13New assessment tools (cognitive batteries)9 kBblankinapplication/pdfehdn-2012-bachoud-levi-empty-file 
08.04.13New assessment tools (cognitive batteries)9 kBblankinapplication/pdfehdn-2012-stout-empty-file 
08.04.13REGISTRY and Enroll-HD9 kBblankinapplication/pdfehdn-2012-landwehrmeyer-empty-file 
08.04.13Poster Awards9 kBblankinapplication/pdfehdn-2012-landwehrmeyer-empty-file 
08.04.13Roundup III33blankintext/x-cms-noteRoundup-III 
08.04.13Progress in HD research and HD advocacy: a personal view9 kBblankinapplication/pdfehdn-2012-sabine-empty-file 
08.04.13EHA meeting33blankintext/x-cms-noteEHA-meeting 
08.04.13Falling in love, staying in love89 kBblankinapplication/pdfeha-2012-mol 
08.04.13Oral Presentations33blankintext/x-cms-noteOral-Presentations 
08.04.13Juvenile Huntington's disease662 kBblankinapplication/pdfa03-juvenile-hd 
08.04.13Default-mode network changes in preclinical Huntington’s disease1.5 MBblankinapplication/pdfa04-default-mode-network-changes 
08.04.13Better global and cognitive functioning for choreatic compared to hypokinetic-rigid Huntington’s disease380 kBblankinapplication/pdfa06-better-global-and-cognitive-functi... 
08.04.13Critical consideration of the criteria for the motor diagnosis of Huntington disease387 kBblankinapplication/pdfa07-critical-consideration-criteria-mo... 
08.04.13Defining predictors of disease2.0 MBblankinapplication/pdfa11-induced-pluripotent-stem-cells 

Folder contains 87 документы/ов.
about us | privacy statement | disclaimer | terms of use